Recombinant Variant of Ciliary Neurotrophic Factor for Weight Loss in Obese Adults: A Randomized, Dose-Ranging Study

JAMA

Volumn 289, Issue 14, 2003, Pages 1826-1832

  Ettinger, Mark P ^b   Littlejohn, Thomas W ^c   Schwartz, Sherwyn L ^d   Weiss, Stuart R ^b   McIlwain, Harris H ^e   Heymsfield, Steven B ^f   Bray, George A ^g   Roberts, William G ^a   Heyman, Eugene R ^h   Stambler, Nancy ^a   Heshka, Stanley ^f   Vicary, Catherine ^a   Guler, Hans Peter ^a  

^a REGENERON PHARMACEUTICALS INC   (United States)

^b RADIANT RESEARCH   (United States)

^c Piedmont Medical Research Associates   (United States)

^d Diabetes and Glandular Disease Clinic   (United States)

^e Tampa Medical Group   (United States)

^f ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^g PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^h Celeris Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT CILIARY NEUROTROPHIC FACTOR; ANTIOBESITY AGENT; CILIARY NEUROTROPHIC FACTOR; INSULIN; LIPID; RECOMBINANT PROTEIN;

ADULT; ARTICLE; BODY MASS; BONE PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HERPES; HUMAN; INFECTION; INJECTION SITE; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; OBESITY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VOMITING; WEIGHT REDUCTION; AGED; BLOOD; CALORIC RESTRICTION; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; ANTI-OBESITY AGENTS; BODY MASS INDEX; CALORIC RESTRICTION; CILIARY NEUROTROPHIC FACTOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INSULIN; LIPIDS; MALE; MIDDLE AGED; OBESITY; RECOMBINANT PROTEINS; WEIGHT LOSS;

EID: 0037687348     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.14.1826     Document Type: Article

References (22)

1. Sendtner M, Carroll P, Holtmann B, Hughes RA, Thoenen H. Ciliary neurotrophic factor. J Neurobiol. 1994;25:1436-1453.
2. Ip NY, Yancopoulos GD. Ciliary neurotrophic factor and its receptor complex. Prog Growth Factor Res. 1992;4:139-155.
3. ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rH-CNTF) in amyotrophic lateral sclerosis. Neurology. 1996;46:1244-1249.
4. Xu B, Dube MG, Kalra W, et al. Anorectic effects of the cytokine, ciliary neurotrophic factor, are mediated by hypothalamic neuropeptide Y: comparison with leptin. Endocrinology. 1998;139:466-473.
5. Panyatatos N, Radzijewska E, Acheson A, Pearsall D, Thadani A, Wong V. Exchange of a single amino acid interconverts the specific activity and gel mobility of human and rat ciliary neurotrophic factors. J Biol Chem. 1993;268:19000-19003.
6. Gloaguen I, Costa P, Demartis A, et al. Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Pro Natl Acad Sci U S A. 1997;94:6456-6461.
7. Lambert PD, Anderson KD, Sleeman MW, et al. Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci U S A. 2001;98:4652-4657.
8. Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 1995;269:540-543.
9. Halaas JL, Gajiwala SK, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995;269:543-546.
10. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science. 1995;269:546-549.
11. Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 1999;282:1568-1575.
12. Mantzoros CS, Flier JS. Leptin as a therapeutic agent-trials and tribulations [editorial]. J Clin Endocrinol Metab. 2000;85:4000-4002.
13. Kalra SP. Circumventing leptin resistance for weight control. Proc Natl Acad Sci U S A. 2001;98:4279-4281.
14. Schofield WN. Predicting basal metabolic rate, new standards and review of previous work. Hum Nutr Clin Nutr. 1985;39:5-41.
15. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med. 2002;346:591-602.
16. Rosenbaum M, Leibel RL, Hirsch J. Obesity. N Engl J Med. 1997;337:396-407.
17. Weintraub M. Long-term weight control study: conclusion. Clin Pharmacol Ther. 1992;51:642-646.
18. Hudson KD. The anorectoic and hypotensive effect of fenfluramine in obesity. J R Coll Gen Pract. 1977;27:497-501.
19. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obesity Res. 1999;7:189-198.
20. Wirth A, Krause J. Long-term weight loss with sibutramine. JAMA. 2001;286:1331-1339.
21. Buchanan TA, Xiang AH, Peters, RK, et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796-2803.
22. Guler HP, Acheson A, Stamber N, Hunt TL, Dato M. Safety study with AXOKINE: a second generation ciliary neurotrophic factor [abstract]. Int J Obes. 2000;24: S102.